{"id":88270,"date":"2026-06-29T08:45:58","date_gmt":"2026-06-29T12:45:58","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/natera-and-aveta-team-up-on-major-head-and-neck-cancer-treatment-study\/"},"modified":"2026-06-29T08:45:58","modified_gmt":"2026-06-29T12:45:58","slug":"natera-and-aveta-team-up-on-major-head-and-neck-cancer-treatment-study","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/natera-and-aveta-team-up-on-major-head-and-neck-cancer-treatment-study\/","title":{"rendered":"Natera and Aveta Team Up on Major Head and Neck Cancer Treatment Study"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

Genetic testing firm Natera and cancer drug developer Aveta Biomics announced Monday that they are joining forces on a large, late-stage clinical trial of an experimental treatment for head and neck cancer, with the goal of better tracking how patients respond to therapy.<\/p>

At the center of the study is Aveta’s APG-157, an experimental oral medication intended to help the body’s immune system fight tumors. The trial will focus on patients diagnosed with locally advanced head and neck cancer.<\/p>

As part of the partnership, Natera’s Signatera test will be used throughout the study to measure molecular residual disease and evaluate how patients are responding to treatment. The test is set to serve as a secondary endpoint in the trial and will be administered before, during, and after treatment.<\/p>

Aveta Biomics said the study aims to enroll approximately 826 patients from sites across North America, Europe, Asia-Pacific, and Australia. The companies said they expect to begin enrolling participants in the second half of 2026.<\/p>

The companies noted that the trial builds on results from an earlier mid-stage study, which showed the therapy helped keep tumors under control and produced encouraging data on patient survival.<\/p>","protected":false},"excerpt":{"rendered":"

Genetic testing company Natera and cancer drug developer Aveta Biomics have announced a partnership to conduct a large-scale late-stage trial of an experimental head and neck cancer therapy. The study will use Natera’s testing technology to track how patients respond to treatment. Enrollment of roughly 826 patients worldwide is expected to begin in the second half of 2026.<\/p>\n","protected":false},"author":4,"featured_media":88269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[837],"tags":[],"class_list":["post-88270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/06\/news-1782737157911.png?fit=1920%2C1080&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-mXI","jetpack-related-posts":[{"id":70252,"url":"https:\/\/tvdelmarva.com\/wp\/new-cancer-treatment-combo-shows-promise-against-melanoma-in-5-year-study\/","url_meta":{"origin":88270,"position":0},"title":"New Cancer Treatment Combo Shows Promise Against Melanoma in 5-Year Study","author":"Admin","date":"May 21, 2026","format":false,"excerpt":"A five-year clinical trial reveals that combining Moderna's experimental cancer vaccine with Merck's Keytruda immunotherapy reduced melanoma spread risk by 59%. The treatment combination showed significantly higher survival rates compared to patients receiving Keytruda alone.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779398670497.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":68218,"url":"https:\/\/tvdelmarva.com\/wp\/pharmaceutical-giant-reports-success-in-uterine-cancer-drug-trial\/","url_meta":{"origin":88270,"position":1},"title":"Pharmaceutical Giant Reports Success in Uterine Cancer Drug Trial","author":"Admin","date":"May 18, 2026","format":false,"excerpt":"Merck announced Monday that its experimental cancer treatment achieved primary objectives in advanced clinical testing for endometrial cancer patients. The drug showed improved survival rates and delayed disease progression compared to traditional chemotherapy in patients whose cancer had advanced despite standard care.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1779103483937.jpg?fit=450%2C295&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":36859,"url":"https:\/\/tvdelmarva.com\/wp\/swiss-pharmaceutical-giant-roche-stock-plunges-after-cancer-drug-trial-setback\/","url_meta":{"origin":88270,"position":2},"title":"Swiss Pharmaceutical Giant Roche Stock Plunges After Cancer Drug Trial Setback","author":"Admin","date":"March 14, 2026","format":false,"excerpt":"Roche's stock value fell over 5% following disappointing results from a clinical trial of their breast cancer medication giredestrant. The experimental oral drug failed to demonstrate effectiveness as a first-line treatment for newly diagnosed patients in a major Phase III study.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1773477396872.jpg?fit=450%2C266&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":62845,"url":"https:\/\/tvdelmarva.com\/wp\/new-pancreatic-cancer-drug-shows-promise-despite-high-side-effect-rate\/","url_meta":{"origin":88270,"position":3},"title":"New Pancreatic Cancer Drug Shows Promise Despite High Side Effect Rate","author":"Admin","date":"May 6, 2026","format":false,"excerpt":"An experimental medication from Revolution Medicines nearly doubled survival times for advanced pancreatic cancer patients in clinical trials, though most participants experienced side effects. The drug, daraxonrasib, targets genetic mutations found in 90% of pancreatic cancers and could become the new standard treatment for patients whose cancer has already spread.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778106220782.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778106220782.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778106220782.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778106220782.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778106220782.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":74478,"url":"https:\/\/tvdelmarva.com\/wp\/new-pancreatic-cancer-pill-shows-promise-in-clinical-trial\/","url_meta":{"origin":88270,"position":4},"title":"New Pancreatic Cancer Pill Shows Promise in Clinical Trial","author":"Admin","date":"May 31, 2026","format":false,"excerpt":"Researchers report that an experimental medication called daraxonrasib helped patients with advanced pancreatic cancer live nearly twice as long compared to traditional chemotherapy. The daily pill targets a mutated protein that drives tumor growth in over 90% of pancreatic cancer cases, offering new hope for one of the most deadly\u2026","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1780231021552.jpg?fit=1000%2C666&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1780231021552.jpg?fit=1000%2C666&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1780231021552.jpg?fit=1000%2C666&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1780231021552.jpg?fit=1000%2C666&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":38255,"url":"https:\/\/tvdelmarva.com\/wp\/pfizers-new-breast-cancer-treatment-shows-40-reduction-in-disease-progression\/","url_meta":{"origin":88270,"position":5},"title":"Pfizer’s New Breast Cancer Treatment Shows 40% Reduction in Disease Progression","author":"Admin","date":"March 17, 2026","format":false,"excerpt":"Pharmaceutical giant Pfizer announced Tuesday that its experimental breast cancer drug combination reduced the risk of disease progression or death by 40% in clinical trials. The treatment combines atirmociclib with hormone therapy fulvestrant and was tested on patients whose cancer had spread and returned after previous treatments.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1773750186502.jpg?fit=450%2C325&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/88270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=88270"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/88270\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/88269"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=88270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=88270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=88270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}